









PRODUCT INFORMATION

Innovax®-ND is a frozen, cell associated, live virus vaccine that contains the recombinant serotype 3 turkey herpesvirus strain with the F gene from Newcastle Disease Virus . It provides proven protection against virulent Newcastle Disease Virus (NDV) and Marek's Disease (MD).

INDICATIONS

Innovax®-ND is recommended for the active immunisation of healthy 18-day-old chicken embryos by the *in-ovo* route or for 1-day-old chickens by the subcutaneous route as an aid in the prevention of Marek's Disease and Newcastle Disease.

STORAGE AND ADMINISTRATION

Innovax®-ND is transported and stored in liquid nitrogen. Innovax®-ND must be thawed and reconstituted using Nobilis® Diluent CA. The vaccine is administered conveniently in the hatchery via injection:

- For subcutaneous vaccination, 0,2 mℓ per chick is injected in the neck.
- For in-ovo vaccination, eggs are injected on the 18th day of the embryo development using 0,05 mℓ per egg.


ONSET OF IMMUNITY

For Marek's Disease the onset of immunity has been demonstrated 5 days after vaccination. For Newcastle Disease, onset of immunity has been demonstrated 2 weeks after vaccination, reaching full immunity at 4 weeks.

ONSET OF IMMUNITY STUDIES


Mexico Chimalhuacan strain ICPI 1.89 - MSD study

- Innovax®-ND onset of immunity was examined in the face of a strong challenge – the Mexico Chimalhuacan strain.
- Maternally immune broilers were used, so at 11 days, the percentage protection is a combination of maternal immunity plus the early onset of immunity from Innovax®-ND that resulted in 70 % protection.
- At 19 days of age 80 % protection was achieved and by 28 days of age this increased to 90 %.



Mexico Chimalhuacan strain - Mexican government trial

- In a study conducted by the Mexican government, MDA positive birds were vaccinated with Innovax®-ND + Nobilis® ND C2 at the hatchery or Innovax®-ND + Nobilis® ND Clone 30 at the hatchery and challenged at the same ages.
- At 11 days, the combination of Innovax®-ND +
 Nobilis® ND C2 achieved 70 % protection.
 However the combination of Innovax®-ND +
 Nobilis® ND Clone 30 achieved 100 % protection
 on the same day.
- By 19 days, both the Innovax®-ND +
 Nobilis® ND C2 and Innovax®-ND + Nobilis® ND
 Clone 30 groups demonstrated 100 % protection.




Competitor onset of immunity to NDV Chimalhuacan strain

Embryonated eggs from commercial broilers with MDA to NDV were assigned to 4 groups:

- Group 1 vaccinated at 18 days of incubation with a competitor HVT-ND.
- Group 2 did not receive an HVT-ND but were vaccinated with a live competitor NDV vaccine via eye drop at hatch.
- Group 3 vaccinated at 18 days of incubation with a competitor HVT-ND and a live competitor NDV vaccine via eye drop at hatch.
- Group 4 did not receive any vaccines = control group.

At various intervals, 10 birds in each group were challenged by eye drop with NDV Chimalhuacan strain, ICPI of 1.89.









HVT MAREK'S DISEASE PROTECTION AT HVT LEVEL

Challenge strain MD GA5


Treatment	Batch	Subcutane	eous route	<i>In-ovo</i> route		
		MDV challenge day 5		MDV challenge day 5		
		Positives/total	% protection	Positives/total	% protection	
Innovax®-ND	Α	4/35	89	4/33	88	
Innovax®-ND	В	1/35	97	3/34	91	
MD challenge control	-	33/34	3	32/34	6	

INNOVAX®-ND DURATION OF IMMUNITY

Duration of immunity against Newcastle Disease has been demonstrated for at least 60 weeks after a single vaccination. The duration of immunity against Marek's Disease will last for the entire risk period.

INNOVAX®-ND DURATION OF IMMUNITY:

% protection by age



COMPATABILITY WITH MAREK'S DISEASE VACCINES

Nobilis® Rismavac and Innovax®-ND are compatible.

Challenged with Marek's Disease at 5 days and Newcastle Disease at 28 days.

Vaccine (route)	Challenge virus		NDV (Texas GB) % Protection	% hatchability
Innovax®-ND (<i>in-ovo</i>)	ND		95	83
Innovax®-ND (s/c)	ND		90	
Nobilis® Rismavac (<i>in-ovo</i>)	MD	94		83
Nobilis® Rismavac (s/c)	MD	97		
Innovax®-ND + Nobilis® Rismavac (in-ovo)	ND+MD	97	90	83
Innovax®-ND + Nobilis® Rismavac (s/c)	ND+MD	100	86	
Not vaccinated	ND+MD	0	0	
Not vaccinated	None	100	100	83

Warning: Do not combine Innovax®-ND with any other conventional HVT vaccine or any competitor recombinant vaccine.

ADVANTAGES

- Provides extended protection for virulent NDV and MD;
- Aids in prevention of Newcastle Disease through at least 60 weeks of age;
- Offers effective protection in the face of NDV maternal antibodies;
- Allows the use of monovalent Infectious Bronchitis (IB) vaccines, improving IB protection;
- Offers flexible administration via in-ovo or subcutaneous injection to fit any vaccination schedule.



